Epidemiological Pattern of COVID-19 Infection from March to November 2020 in Situbondo District, East Java, Indonesia

Mohmed Gesmalah, Atik Choirul Hidajah


The COVID-19 pandemic continues to pose a global threat. As of March 31, 2020, there were 1,528 confirmed COVID-19 cases with 136 deaths in Indonesia. This study aimed to describe the epidemiological features and clinical course of COVID-19 in Situbondo District, East Java Province, Indonesia, to facilitate understanding of the epidemiological situation and the spread of infection in the community to improve the control and prevention measures. This study examined the epidemiological features of COVID-19 cases in Situbondo using descriptive analysis. The results revealed that from March to November 2020, there were 1,622 suspected cases and 816 confirmed cases. Moreover, females (total case 470,58%) were more likely to be infected than males (total case 346,43%). Mainly, the cases of COVID-19 infection were in the age group of 19-37 years old (36.8%), and almost half of the confirmed cases (41 cases) were caused by the infection from close contact to confirmed cases, based on the epidemiological investigation report. People with comorbidities were more susceptible to being infected. Hypertension (8,7%), diabetes (8,6%), heart disease (3,7%), kidney failure, and COPD, each by (1%) were the highest reported comorbidities in COVID-19 patients. There was another disease with a low percentage like asthma, pulmonary TB, and cancer. This study opens the gate to further studies, which are needed to understand more about the epidemiological COVID-19 situation in the community.


COVID-19, epidemiological pattern, infection, Situbondo

Full Text:



 1.Lotfi M, Hamblin MR, Rezaei N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254–66.

 2.Setiati S, Azwar MK. COVID-19 and Indonesia. Acta Med Indones.2020;53:7.

 3.Adhikari SP, Meng S, Wu Y, Mao Y, Ye R, Wang Q, et al. A scoping review of 2019 Novel Coronavirus during the early outbreak period: epidemiology, causes, clinical manifestation and diagnosis, prevention and control. Infect Dis Poverty BMC; 2020.

 4.Dong R, Pei S, Yin C, He RL, Yau SST. Analysis of the hosts and transmission paths of SARS-CoV-2 in the COVID-19 outbreak. Genes (Basel). 2020;11(6):637.

 5.Dhama K, et al. Coronavirus disease 2019–COVID-19. Am Soc Microbiol. 2020;33(4):1–48.

 6.Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–8.

 7.World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Geneva World Heal Organ; 2020.

 8.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus–Infected pneumonia. N Engl J Med. 2020;382(13):1199–207.

 9.Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441–7.

 10.Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in hu-man: a descriptive study. Chin Med J (Engl). 2020;133(9):1015–24.

 11.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

 12.Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. Journal of Medical Virology. 2020;92:797–806.

 13.Guan W, Liang W, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J.2020;74(10):14.

 14.Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA - J Am Med Assoc. 2020;323(20):2052–9.

 15.Satuan Tugas Penanganan COVID-19. Analisis data COVID-19 Indonesia per 15 november 2020; 2020.

 16.Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

 17.Albitar O, Ballouze R, Ping J, Maisharah S, Ghadzi S. Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract. 2020;166.

 18.Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006Jun;23(6):623–8.

 19.Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Heal. 2020;8:1–6.

 20.Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United. MMWR Morb Mortal Wkly Rep.


 21.Mudd T. World view. Ind Week. 2000;249(16):40–1.

 22.Alwan NA. Surveillance is underestimating the burden of the COVID-19 pandemic. Lancet. 2020;396(10252):e24.

 23.Ortiz N, Villarino E, Lee JT, Bajema KL, Ricaldi JN, Smith S, et al. Epidemiologic findings from case investigations and contact tracing for first 200 cases of coronavirus disease, Santa Clara County, California, USA. Emerg Infect Dis. 2021;27(5):1301–8.

 24.Lee LYK, Lam EPW, Chan CK, Chan SY, Chiu MK, Chong WH, et al. Practice and technique of using face mask amongst adults in the community: a cross-sectional descriptive study. BMC Public Health. 2020;20(1):1–11.

 25.Das S, K.R. A, Birangal SR, Nikam AN, Pandey A, Mutalik S, et al. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: a review. Life Sciences. 2020;258.

 26.Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–22.

 27.Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension andCOVID-19. American Journal of Hypertension. 2020;33:373–4.

 28.Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al.Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. LancetDiabetes Endocrinol. 2020;8(10):823–33.

DOI: http://dx.doi.org/10.21109/kesmas.v0i0.5049


  • There are currently no refbacks.